Remicade monotherapy approved for psoriatic arthritis

The monoclonal antibody, Remicade (infliximab) has been approved for use as monotherapy in the treatment of active and progressive psoriatic arthritis that has responded inadequately to disease-modifying anti-rheumatic drugs in patients where methotrexate is contraindicated or not tolerated.

Previously, Remicade was licensed only for use in combination with methotrexate to treat the condition.
The recommended dosage is 5mg/kg by intravenous infusion over a two-hour period, repeated two and six weeks after the first infusion and then every six to eight weeks.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Prescribing infant formulae made easier with new MIMS table

Prescribing infant formulae made easier with new MIMS table

MIMS has published a quick-reference comparison table...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New name for Humalog insulin biosimilar

New name for Humalog insulin biosimilar

Admelog (insulin lispro) is a biosimilar of the rapid-acting...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...